Stanley R. Frankel

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.

G. Rosner, H. Kantarjian, G. Garcia-Manero, 2008, Blood.

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).

Chunlei Zhang, Madeleine Duvic, M. Duvic, 2007, Blood.